Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Travera Inc
Arvinas Inc.
Novartis
AstraZeneca
Revolution Medicines, Inc.
Tempus AI
Massive Bio, Inc.
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Tempus AI
Vyriad, Inc.
Immunophotonics, Inc.
Taproot Health
VitaMed Research LLC
ADC Therapeutics S.A.
Sanguine Biosciences
Klus Pharma Inc.
Kineta Inc.
Genzada Pharmaceuticals USA, Inc.
Provectus Pharmaceuticals
TScan Therapeutics, Inc.
MacroGenics
SpeciCare
Asana BioSciences
Lumos Pharma
Sichuan Huiyang Life Science and Technology Corporation
Cota Inc.
MedInnovation GmbH
Novartis
Merck Sharp & Dohme LLC
INSYS Therapeutics Inc
Calando Pharmaceuticals
Delcath Systems Inc.
Pfizer
Altor BioScience
GammaCan